Latest news about Sandu Pharmaceuticals
Sandu Pharmaceuticals
38.47
+1.28(+3.44%)
Company Performance:
View Company Insights1D+3.44%
1M+3.97%
6M-11.58%
1Y-27.35%
5Y-6.40%
More news about Sandu Pharmaceuticals
24Jan 26
Sandu Pharmaceuticals Limited Schedules Board Meeting on February 06, 2026 for Q3FY26 Financial Results Approval
Sandu Pharmaceuticals Limited has scheduled a board meeting for February 06, 2026, at 04:00 PM to approve standalone unaudited financial results for the quarter ended December 31, 2025. The meeting will be held at the company's Mumbai corporate office. In compliance with SEBI insider trading regulations, the company has closed the trading window for directors, officers, and designated employees from January 01, 2026, until 48 hours after the public announcement of quarterly results.
22Dec 25
Sandu Pharmaceuticals Receives GST Notice for ₹13.00 Lakh Discrepancy
Sandu Pharmaceuticals Limited has received a notice from the Maharashtra Department of Goods and Service Tax regarding discrepancies in its GST returns. The notice, issued on December 22, identifies a ₹13.00 lakh discrepancy related to non-reversal of Input Tax Credit in GSTR-3B compared to GSTR-9. The company plans to file a reply and expects a favorable outcome based on internal assessment and legal advice. Sandu Pharmaceuticals anticipates no material impact on its financials or operations.
19Nov 25
Sandu Pharmaceuticals Shareholders Approve Reclassification of Akshath Finvest from Promoter to Public Category
Sandu Pharmaceuticals Limited (SPL) shareholders have approved the reclassification of Akshath Finvest and Properties Private Limited from 'Promoter/Promoter Group' to 'Public' category. This involves 4,94,182 shares (5.12% of SPL's shareholding). The resolution passed with 92.02% votes in favor. As a result, promoter shareholding decreases from 42.90% to 37.79%, while public shareholding increases from 57.10% to 62.21%. The reclassification is pending approval from BSE Limited and other statutory authorities.
17Oct 25
Sandu Pharmaceuticals Seeks Shareholder Approval for Promoter Reclassification
Sandu Pharmaceuticals Limited has initiated a process to reclassify Akshath Finvest and Properties Private Limited from the promoter category to public category. The company is seeking shareholder approval through a postal ballot. Akshath Finvest currently holds 4,94,182 shares (5.12% of paid-up equity share capital). The Bombay Stock Exchange has granted approval for the reclassification, subject to shareholder consent. E-voting is scheduled from October 20, 2025, to November 18, 2025, with results expected by November 20, 2025. The reclassification aligns with SEBI's Listing Obligations and Disclosure Requirements Regulations.
14Oct 25
Sandu Pharmaceuticals Board Approves Postal Ballot for Promoter Reclassification
Sandu Pharmaceuticals Limited's Board of Directors has approved a postal ballot notice to seek shareholder approval for reclassifying M/s Akshath Finvest and Properties Private Limited from 'Promoter/Promoter Group' to 'Public' category. The e-voting process, with a cut-off date of October 15, 2025, will determine the outcome of this proposed change in the company's ownership structure.
15Aug 25
Sandu Pharmaceuticals Reports 33.8% Jump in Q1 Net Profit Despite Revenue Decline
Sandu Pharmaceuticals Limited reported mixed Q1 results with a 2.2% decrease in total income to ₹1,671.67 lakhs. However, net profit after tax increased by 33.8% to ₹22.33 lakhs, and earnings per share improved from ₹0.17 to ₹0.23. The company's operating profit margin was 3.17%, slightly lower than the previous quarter. The board approved these results on August 13.
13Aug 25
Sandu Pharmaceuticals Reports Q1 Profit, Declares Dividend, and Schedules 40th AGM
Sandu Pharmaceuticals reported Q1 revenue of Rs 1665.90 lakhs and profit after tax of Rs 22.33 lakhs. The Board declared a dividend of Rs 0.80 per share (8% of paid-up capital). The 40th AGM is scheduled for September 30 via video conferencing, with a book closure period from September 23-30. The company approved continuation of material related party transactions with Sandu Brothers Private Limited and the extension of CFO Shri Vijay Kajarekar's tenure beyond 70 years, both subject to shareholder approval.
16Jun 25
Sun Pharma's Halol Facility Faces FDA Scrutiny; Leadership Transition Announced
Sun Pharmaceuticals received eight FDA observations for its Halol facility, which is already under import alert. The company also announced a leadership transition, with Kirti Ganorkar set to become Managing Director on September 1, 2025, succeeding founder Dilip Shanghvi.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Lupin
Mankind Pharma
Zydus Life Science
Aurobindo Pharma
Laurus Labs
1,878.20
(+0.81%)
6,760.50
(-2.33%)
4,405.70
(+0.04%)
1,432.10
(-0.32%)
1,336.70
(+2.54%)
2,276.20
(+0.80%)
2,503.00
(+1.66%)
1,011.70
(+2.02%)
1,511.80
(+0.06%)
1,323.60
(+0.62%)
Get More Market Insights with
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
